“[Our share price] has been impacted by the effect of COVID-19 on cross-border e-commerce into China and like all things with COVID-19, hopefully, will pass,” he said. “Then the negative drag on our results and share price will be removed.”
McPherson’s board has advised shareholders in the 48-page statement, released on Thursday, to await the completion of the operational review into the business.
However, Gallin has called on McPherson’s to provide a trading update before May and give more clarity on the performance of its recent $27 million acquisition of vitamins brand Global Therapeutics.
McPherson’s newly-minted chief executive Grant Peck said the company would wait until it had further certainty about its performance in…